OPTIMARK IN PLASTIC CONTAINER Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Optimark In Plastic Container, and what generic alternatives are available?
Optimark In Plastic Container is a drug marketed by Liebel-flarsheim and is included in one NDA.
The generic ingredient in OPTIMARK IN PLASTIC CONTAINER is gadoversetamide. There is one drug master file entry for this compound. Additional details are available on the gadoversetamide profile page.
Summary for OPTIMARK IN PLASTIC CONTAINER
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| Clinical Trials: | 3 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | OPTIMARK IN PLASTIC CONTAINER at DailyMed |
Recent Clinical Trials for OPTIMARK IN PLASTIC CONTAINER
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Bayer | Phase 2 |
| Mallinckrodt | Phase 1 |
| University of Miami | Phase 1 |
Anatomical Therapeutic Chemical (ATC) Classes for OPTIMARK IN PLASTIC CONTAINER
US Patents and Regulatory Information for OPTIMARK IN PLASTIC CONTAINER
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liebel-flarsheim | OPTIMARK IN PLASTIC CONTAINER | gadoversetamide | INJECTABLE;INJECTION | 020976-002 | Dec 8, 1999 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Liebel-flarsheim | OPTIMARK IN PLASTIC CONTAINER | gadoversetamide | INJECTABLE;INJECTION | 020976-001 | Dec 8, 1999 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Liebel-flarsheim | OPTIMARK IN PLASTIC CONTAINER | gadoversetamide | INJECTABLE;INJECTION | 020976-003 | Dec 8, 1999 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Liebel-flarsheim | OPTIMARK IN PLASTIC CONTAINER | gadoversetamide | INJECTABLE;INJECTION | 020976-004 | Dec 8, 1999 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for OPTIMARK IN PLASTIC CONTAINER
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Liebel-flarsheim | OPTIMARK IN PLASTIC CONTAINER | gadoversetamide | INJECTABLE;INJECTION | 020976-001 | Dec 8, 1999 | ⤷ Try a Trial | ⤷ Try a Trial |
| Liebel-flarsheim | OPTIMARK IN PLASTIC CONTAINER | gadoversetamide | INJECTABLE;INJECTION | 020976-001 | Dec 8, 1999 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
EU/EMA Drug Approvals for OPTIMARK IN PLASTIC CONTAINER
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| Mallinckrodt Deutschland GmbH | Optimark | gadoversetamide | EMEA/H/C/000745 This medicinal product is for diagnostic use only.Optimark is indicated for use with magnetic resonance imaging (MRI) of the central nervous system (CNS) and liver. It provides contrast enhancement and facilitates visualisation and helps with the characterisation of focal lesions and abnormal structures in the CNS and liver in patients with known or highly suspected pathology. |
Withdrawn | no | no | no | 2007-07-23 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for OPTIMARK IN PLASTIC CONTAINER
See the table below for patents covering OPTIMARK IN PLASTIC CONTAINER around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Germany | 68927173 | ⤷ Try a Trial | |
| Austria | 142614 | ⤷ Try a Trial | |
| Singapore | 49063 | Novel magnetic resonance imaging agents | ⤷ Try a Trial |
| Japan | 2815556 | ⤷ Try a Trial | |
| Germany | 122007000068 | ⤷ Try a Trial | |
| Japan | H0920785 | NONIONIC PARAMAGNETIC ION COMPLEX AND COMPLEXING AGENT FOR FORMING THE SAME | ⤷ Try a Trial |
| Netherlands | 300299 | ⤷ Try a Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for OPTIMARK IN PLASTIC CONTAINER
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0425571 | 07C0052 | France | ⤷ Try a Trial | PRODUCT NAME: GADOVERSETAMIDE (CHELATE CONTENANT DU GADOLILIUM ET DE LA VERSETAMIDE); REGISTRATION NO/DATE IN FRANCE: EU/1/07/398/001 DU 20070723; REGISTRATION NO/DATE AT EEC: EU/1/07/398/001 DU 20070723 |
| 0425571 | 300299 | Netherlands | ⤷ Try a Trial | 300299, 20090719, EXPIRES: 20140718 |
| 0425571 | 2007C/064 | Belgium | ⤷ Try a Trial | PRODUCT NAME: GADOVERSETAMIDE; REGISTRATION NO/DATE: EU/1/07/398/001 20070724 |
| 0425571 | SPC/GB07/052 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: GADOVERSETAMIDE (A CHELATE CONTAINING GADOLINIUM AND VERSETAMIDE); REGISTERED: UK EU/1/07/398/001 20070723; UK EU/1/07/398/002 20070723; UK EU/1/07/398/003 20070723; UK EU/1/07/398/004 20070723 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
